Brief: Ascletis Pharma Inc - First Subject Dosed In Phase Ii Clinical Trial Of Asc22 (Envafolimab) For Immune Restoration/ Functional Cure Of Hiv-1 Infection
28/06/2022 11:14
June 28 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS PHARMA INC - FIRST SUBJECT DOSED IN PHASE II
CLINICAL
TRIAL OF ASC22 (ENVAFOLIMAB) FOR IMMUNE RESTORATION/ FUNCTIONAL
CURE OF HIV-1 INFECTION
* ASCLETIS PHARMA INC - PHASE II CLINICAL STUDY IN CHINA IS
CURRENTLY EXPECTED TO BE COMPLETED IN EARLY 2023 WITH AN
EXPECTED ENROLLMENT OF 30 SUBJECTS
Source text for Eikon: ID:nPn7PHJgWa
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026